AR043199A1 - Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes - Google Patents
Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentesInfo
- Publication number
- AR043199A1 AR043199A1 ARP040100483A ARP040100483A AR043199A1 AR 043199 A1 AR043199 A1 AR 043199A1 AR P040100483 A ARP040100483 A AR P040100483A AR P040100483 A ARP040100483 A AR P040100483A AR 043199 A1 AR043199 A1 AR 043199A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- nrara
- pharmaceutically acceptable
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se relaciona con nuevos compuestos heterocíclicos, sus análogos, sus tautómeros, sus regioisómeros, sus estereoisómeros, sus enantiómeros, sus diasterómeros, sus polimorfos, sus sales farmacéuticamente aceptables, sus N-óxidos apropiados, sus solvatos farmacéuticamente aceptables y las composiciones farmacéuticas que los contienen. Más particularmente, la presente se relaciona con nuevos inhibidores de fosfodiesterasa tipo 4 (PDE4) de fórmula (1), sus análogos, sus tautómeros, sus enantiómeros, sus diasterómeros, sus regioisómeros, sus estereoisómeros, sus polimorfos, sus sales farmacéuticamente aceptables, sus N-óxidos apropiados, sus solvatos farmacéuticamente aceptables y las composiciones farmacéuticas que los contienen. Estos compuestos tienen actividad anti-inflamatoria y antialérgica. Reivindicación 1: Un compuesto de fórmula general (1) en donde: R1, R2 y R3 pueden ser iguales o diferentes, e independientemente seleccionados en cada caso desde grupos que consisten en H, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, grupo heterocíclico sustituido o no sustituido, heterociclialquilo sustituido o no sustituido, heteroarilalquilo sustituido o no sustituido, nitro, -OH, ciano, formilo, acetilo, halógeno, grupos protectores, -C(O)-Ra, -C(O)O-Ra, -C(O)NRaRa, -S(O)q-Ra, -S(O)q-NRaRa, -NRaRa, -ORa, -SRa, o cuando dos sustituyentes R3 se encuentran en posición orto entre sí, pueden estar unidos para formar un anillo de 3 -7 miembros saturado o no saturado que opcionalmente puede incluir hasta dos heteroátomos que pueden ser idénticos o diferentes seleccionados de entre O, NRa o S; en la cual R4 es -NR5R6; en la cual R5 y R6 pueden ser idénticos o diferentes y son independientemente seleccionados de entre grupos consistentes en H, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, anillo heterocíclico sustituido o no sustituido, heterociclialquilo sustituido o no sustituido, heteroarilalquilo sustituido o no sustituido, nitro, -OH, halógeno, -C(O)-Ra, -C(O)O-Ra, -C(O)NRaRa, -S(O)q-Ra, -S(O)q-NRaRa, -C(=NRa)-Ra, -C(=NRa)NRaRa, -C(=S)-NRaRa, -C(=S)-Ra, -N=C(RaRa), -NRaRa, -ORa, -SRa, grupos protectores, o R5 y R6 pueden estar unidos entre sí para formar un anillo cíclico de 3-7 miembros saturado o no saturado, que opcionalmente puede incluir hasta dos heteroátomos que pueden ser idénticos o diferentes, seleccionados de entre O, NRa o S; Ar es seleccionado del grupo consistente en arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, anillo heterocíclico sustituido o no sustituido, o anillo heteroarilo sustituido o no sustituido; X se selecciona de entre el grupo consistente en O, S(O)q y NRa; Y se selecciona de entre el grupo consistente en -C(O)NR7, -NR7S(O)q, S(O)qNR7 y -NR7C(O); R7 se selecciona de entre el grupo consistente en H, alquilo sustituido o no sustituido, hidroxilo, -ORa, arilo sustituido o no sustituido, y anillo heterocíclico sustituido o no sustituido; en la cual p se selecciona de entre el grupo consistente en O y S; en la cual m representa 0-3; en la cual n representa 1-4; en la cual q representa 0, 1, o 2; siempre que R4 no sea NH2; en la cual Ra es seleccionado del grupo consistente en H, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, anillo heterocíclico sustituido o no sustituido, heterociclialquilo sustituido o no sustituido, heteroarilalquilo sustituido o no sustituido, nitro, -OH, ciano, formilo, acetilo, halógeno, grupos protectores, -C(O)Ra, -C(O)O-Ra, C(O)NRaRa, S(O)q-Ra, S(O)q-NRaRa, -NRaRa, -ORa, y SRa; y sus análogos, sus tautómeros, sus regioisómeros, sus estereoisómeros, sus enantiómeros, sus diastereómeros, sus polimorfos, sus sales farmacéuticamente aceptables, sus N-óxidos, sus solvatos farmacéuticamente aceptables y las composiciones farmacéuticas que los contengan o las sales farmacéuticamente aceptables de los mismos con la previsión de que no se incluya la siguiente estructura.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN363MU2003 | 2003-04-11 | ||
| US51996703P | 2003-11-13 | 2003-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043199A1 true AR043199A1 (es) | 2005-07-20 |
Family
ID=36947516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100483A AR043199A1 (es) | 2003-04-11 | 2004-02-17 | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US7223789B2 (es) |
| EP (1) | EP1620429B1 (es) |
| JP (1) | JP2006522789A (es) |
| KR (1) | KR20060017494A (es) |
| CN (1) | CN1829711B (es) |
| AP (1) | AP2008A (es) |
| AR (1) | AR043199A1 (es) |
| AT (1) | ATE427308T1 (es) |
| AU (1) | AU2004228453B2 (es) |
| BR (1) | BRPI0409747A (es) |
| CA (1) | CA2522023A1 (es) |
| CL (1) | CL2004000526A1 (es) |
| CO (1) | CO5700824A2 (es) |
| DE (1) | DE602004020332D1 (es) |
| DK (1) | DK1620429T3 (es) |
| EA (1) | EA010634B1 (es) |
| ES (1) | ES2320888T3 (es) |
| GE (1) | GEP20084526B (es) |
| HR (1) | HRP20050944A2 (es) |
| IS (1) | IS8123A (es) |
| MA (1) | MA27801A1 (es) |
| MX (1) | MXPA05010948A (es) |
| MY (1) | MY136516A (es) |
| NO (1) | NO20055316L (es) |
| NZ (1) | NZ542882A (es) |
| OA (1) | OA13154A (es) |
| PL (1) | PL378813A1 (es) |
| PT (1) | PT1620429E (es) |
| SI (1) | SI1620429T1 (es) |
| TN (1) | TNSN05252A1 (es) |
| TW (1) | TW200508212A (es) |
| UA (1) | UA79558C2 (es) |
| WO (1) | WO2004089940A1 (es) |
| ZA (1) | ZA200508240B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037805A1 (en) * | 2002-10-23 | 2004-05-06 | Glenmark Pharmaceuticals Ltd. | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| ATE427308T1 (de) * | 2003-04-11 | 2009-04-15 | Glenmark Pharmaceuticals Sa | Neue heterozyklische verbindungen, die sich fur die behandlung von entzundlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten |
| CA2583497A1 (en) * | 2004-10-13 | 2006-04-20 | Glenmark Pharmaceuticals S.A. | Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide |
| WO2006051390A1 (en) * | 2004-11-10 | 2006-05-18 | Glenmark Pharmaceuticals S.A. | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, pharmaceutical compositions containing them, and methods of preparing them |
| KR101317119B1 (ko) * | 2004-12-17 | 2013-10-11 | 그렌마크 파머수티칼스 에스. 아. | 염증성 및 알레르기성 장애의 치료에 유용한 신규한헤테로사이클릭 화합물 |
| PT1831227E (pt) | 2004-12-17 | 2013-08-23 | Glenmark Pharmaceuticals Sa | Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CN101484166B (zh) | 2006-07-05 | 2012-09-05 | 奈科明有限责任公司 | 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合 |
| US7511150B2 (en) * | 2006-07-06 | 2009-03-31 | Forest Laboratories Holdings Limited | Synthesis of heterocyclic compounds |
| US20100056791A1 (en) * | 2006-09-01 | 2010-03-04 | Yasushi Kohno | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
| JPWO2008029829A1 (ja) * | 2006-09-06 | 2010-01-21 | 杏林製薬株式会社 | ピラゾロピリジン誘導体及びそれらを有効成分とするホスホジエステラーゼ（ｐｄｅ）阻害剤 |
| NZ575389A (en) * | 2006-09-11 | 2012-03-30 | Mylan Lab Ltd | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| JP2010507674A (ja) * | 2006-10-27 | 2010-03-11 | ワイス エルエルシー | マトリクスメタロプロテアーゼ阻害剤としての三環式化合物 |
| WO2008065522A2 (en) * | 2006-11-29 | 2008-06-05 | Glenmark Pharmaceuticals S.A. | Process for the synthesis of 4-difluoromethoxy-8-nitro-1-formyl dibenzo[b,d] furan-an intermediate for pde iv inhibitors |
| AR064307A1 (es) * | 2006-12-13 | 2009-03-25 | Gilead Sciences Inc | Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion. |
| BRPI0806447A2 (pt) * | 2007-02-09 | 2011-09-06 | Forest Laboratoires Holdings Ltd | formulação de compostos heterocìclicos, método para tratar condição inflamatória ou alérgica e forma amorfa sustancialmente pura de um composto |
| US8524905B2 (en) | 2007-05-22 | 2013-09-03 | Glenmark Pharmaceuticals S.A. | Processes for preparing 6-(difluoromethoxy)[1]benzofuro[3,2-c]pyridine-9-carbaldehyde, a novel intermediate for the synthesis of PDE IV inhibitors |
| US20110171195A1 (en) * | 2007-06-15 | 2011-07-14 | Duke University | Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp |
| EP2070913A1 (en) | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
| WO2009147476A1 (en) * | 2008-06-02 | 2009-12-10 | Matrix Laboratories Ltd. | Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation |
| TWI474282B (zh) * | 2008-10-03 | 2015-02-21 | Himax Tech Ltd | 深度相關的影像加強 |
| AU2009335821A1 (en) | 2008-12-19 | 2010-07-15 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| WO2011132051A2 (en) * | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| PL2651965T3 (pl) * | 2010-12-15 | 2019-04-30 | Contravir Pharmaceuticals Inc | Cząsteczki analogów cyklosporyny modyfikowane w aminokwasach 1 i 3 |
| JP6225161B2 (ja) * | 2013-02-28 | 2017-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 呼吸器疾患の予防治療剤 |
| CN104177612A (zh) * | 2013-05-28 | 2014-12-03 | 韩文毅 | 一种新的非线性聚合物及其制备和用途 |
| CN104211947A (zh) * | 2013-05-31 | 2014-12-17 | 韩文毅 | 一种非线性聚合物及其制备和用途 |
| CN104211950A (zh) * | 2013-06-04 | 2014-12-17 | 韩文毅 | 一种非线性聚合物及其制备与用途 |
| CN104211949A (zh) * | 2013-06-04 | 2014-12-17 | 韩文毅 | 一种非线性聚合物及其制备与用途 |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| DK3377488T3 (da) | 2015-11-19 | 2022-10-03 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| ES2844374T3 (es) | 2015-12-22 | 2021-07-22 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| RU2616617C1 (ru) * | 2016-04-12 | 2017-04-18 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук | 5-(9-этил-9Н-карбазол-3-ил)-4-[5-(9-этил-9Н-карбазол-3-ил)-тиофен-2-ил]-пиримидин |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| PE20190731A1 (es) | 2016-06-20 | 2019-05-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| IL295660A (en) | 2016-12-22 | 2022-10-01 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
| FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| CN109651232A (zh) * | 2018-12-12 | 2019-04-19 | 河北华清光电材料有限公司 | 制备4-溴咔唑及其衍生物的方法 |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| PH12022550754A1 (en) | 2019-09-30 | 2023-08-23 | Incyte Corp | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| KR20220101664A (ko) | 2019-11-11 | 2022-07-19 | 인사이트 코포레이션 | Pd-1/pd-l1 억제제의 염 및 결정질 형태 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| AU2021373044A1 (en) | 2020-11-06 | 2023-06-08 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| CN114163417B (zh) * | 2021-12-06 | 2023-08-04 | 郑州海阔光电材料有限公司 | 一种3-溴硫芴的合成方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1041861A (en) | 1962-03-14 | 1966-09-07 | Organon Labor Ltd | Pyrrolidone derivatives and pharmaceutical preparations containing them |
| NL7008628A (es) * | 1969-06-25 | 1970-12-29 | ||
| US3759948A (en) * | 1969-06-25 | 1973-09-18 | Merck & Co Inc | Non-steroid anti-inflammatory compounds |
| US3846553A (en) * | 1969-12-03 | 1974-11-05 | Merck & Co Inc | 3-substituted-2-pyridones in the treatment of pain, fever or inflammation |
| NL7016899A (es) | 1969-12-03 | 1971-06-07 | ||
| US4222944A (en) * | 1978-07-31 | 1980-09-16 | Hoffmann-La Roche Inc. | Halo-3-dibenzofuran alkanonitriles |
| JPS62158253A (ja) | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | ４−アミノピリジンアミド誘導体 |
| JPH0812430B2 (ja) | 1986-07-07 | 1996-02-07 | キヤノン株式会社 | 電子写真感光体 |
| US5202344A (en) | 1990-12-11 | 1993-04-13 | G. D. Searle & Co. | N-substituted lactams useful as cholecystokinin antagonists |
| IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
| WO1993019747A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| DK0652868T3 (da) | 1992-07-28 | 2005-02-14 | Aventis Pharma Ltd | Hæmmere af c-AMP-phosphodiesterase |
| MX9306311A (es) * | 1992-10-13 | 1994-04-29 | Smithkline Beecham Plc | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
| US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| DE122010000043I1 (de) | 1993-07-02 | 2011-01-27 | Nycomed Gmbh | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
| WO1995009837A1 (en) | 1993-10-01 | 1995-04-13 | Smithkline Beecham Corporation | Cyano compounds |
| GB9401460D0 (en) | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
| GB9404706D0 (en) | 1994-03-11 | 1994-04-27 | Smithkline Beecham Corp | Compounds |
| AU686426B2 (en) | 1994-07-27 | 1998-02-05 | Sankyo Company Limited | Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors |
| KR20000068414A (ko) * | 1996-09-04 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도 |
| WO1999047545A2 (en) | 1998-03-19 | 1999-09-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
| US6110962A (en) * | 1998-05-12 | 2000-08-29 | American Home Products Corporation | 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia |
| CA2330623A1 (en) | 1998-05-12 | 1999-11-18 | Zenan Li | 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia |
| US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| MXPA02009020A (es) | 2000-03-17 | 2003-02-12 | Du Pont Pharm Co | Derivados de beta-aminoacidos ciclicos como inhibidores de las metaloproteasas de matriz y factor de necrosis de tumor alfa. |
| US6924292B2 (en) | 2000-03-23 | 2005-08-02 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivatives, process for producing the same and use thereof |
| JP4224566B2 (ja) * | 2000-12-18 | 2009-02-18 | 株式会社医薬分子設計研究所 | 炎症性サイトカイン産生遊離抑制剤 |
| WO2002060867A2 (en) * | 2001-01-29 | 2002-08-08 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| WO2002072567A2 (en) | 2001-03-13 | 2002-09-19 | Glenmark Pharmaceuticals Limited | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| TW200302726A (en) * | 2002-01-31 | 2003-08-16 | Ono Pharmaceutical Co | Nitrogen-containing bicyclic compound and medicament containing same as active ingredient |
| AU2003253130A1 (en) | 2002-08-19 | 2004-03-03 | Glenmark Pharmaceuticals Limited | Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders |
| WO2004022536A1 (en) | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| WO2004037805A1 (en) * | 2002-10-23 | 2004-05-06 | Glenmark Pharmaceuticals Ltd. | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| ATE427308T1 (de) * | 2003-04-11 | 2009-04-15 | Glenmark Pharmaceuticals Sa | Neue heterozyklische verbindungen, die sich fur die behandlung von entzundlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten |
| PT1831227E (pt) * | 2004-12-17 | 2013-08-23 | Glenmark Pharmaceuticals Sa | Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas |
-
2004
- 2004-02-11 AT AT04710093T patent/ATE427308T1/de not_active IP Right Cessation
- 2004-02-11 NZ NZ542882A patent/NZ542882A/en unknown
- 2004-02-11 BR BRPI0409747-5A patent/BRPI0409747A/pt not_active IP Right Cessation
- 2004-02-11 JP JP2006506259A patent/JP2006522789A/ja active Pending
- 2004-02-11 PT PT04710093T patent/PT1620429E/pt unknown
- 2004-02-11 WO PCT/IB2004/000355 patent/WO2004089940A1/en active Application Filing
- 2004-02-11 DK DK04710093T patent/DK1620429T3/da active
- 2004-02-11 AP AP2005003424A patent/AP2008A/xx active
- 2004-02-11 SI SI200431133T patent/SI1620429T1/sl unknown
- 2004-02-11 CA CA002522023A patent/CA2522023A1/en not_active Abandoned
- 2004-02-11 DE DE602004020332T patent/DE602004020332D1/de not_active Expired - Lifetime
- 2004-02-11 PL PL378813A patent/PL378813A1/pl not_active Application Discontinuation
- 2004-02-11 AU AU2004228453A patent/AU2004228453B2/en not_active Expired - Fee Related
- 2004-02-11 OA OA1200500280A patent/OA13154A/en unknown
- 2004-02-11 CN CN2004800160486A patent/CN1829711B/zh not_active Expired - Fee Related
- 2004-02-11 MX MXPA05010948A patent/MXPA05010948A/es active IP Right Grant
- 2004-02-11 GE GEAP20049048A patent/GEP20084526B/en unknown
- 2004-02-11 ES ES04710093T patent/ES2320888T3/es not_active Expired - Lifetime
- 2004-02-11 KR KR1020057019359A patent/KR20060017494A/ko not_active Application Discontinuation
- 2004-02-11 EA EA200501617A patent/EA010634B1/ru not_active IP Right Cessation
- 2004-02-11 EP EP04710093A patent/EP1620429B1/en not_active Expired - Lifetime
- 2004-02-17 AR ARP040100483A patent/AR043199A1/es unknown
- 2004-02-24 TW TW093104603A patent/TW200508212A/zh unknown
- 2004-03-09 MY MYPI20040813A patent/MY136516A/en unknown
- 2004-03-15 CL CL200400526A patent/CL2004000526A1/es unknown
- 2004-04-09 US US10/821,642 patent/US7223789B2/en not_active Expired - Lifetime
- 2004-11-02 UA UAA200510680A patent/UA79558C2/uk unknown
-
2005
- 2005-10-06 TN TNP2005000252A patent/TNSN05252A1/en unknown
- 2005-10-12 ZA ZA200508240A patent/ZA200508240B/en unknown
- 2005-11-04 HR HR20050944A patent/HRP20050944A2/xx not_active Application Discontinuation
- 2005-11-09 MA MA28593A patent/MA27801A1/fr unknown
- 2005-11-10 IS IS8123A patent/IS8123A/is unknown
- 2005-11-10 NO NO20055316A patent/NO20055316L/no not_active Application Discontinuation
- 2005-11-11 CO CO05115151A patent/CO5700824A2/es not_active Application Discontinuation
-
2006
- 2006-09-28 US US11/536,434 patent/US7384962B2/en not_active Expired - Fee Related
- 2006-09-28 US US11/536,448 patent/US7393846B2/en not_active Expired - Fee Related
-
2008
- 2008-06-02 US US12/131,286 patent/US20090182143A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043199A1 (es) | Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes | |
| AR053415A1 (es) | Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion | |
| AR055057A1 (es) | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. | |
| AR041661A1 (es) | Compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos procesos para su preparacion y composiciones farmaceuticas que lo contienen | |
| AR036663A1 (es) | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestos | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR068045A1 (es) | Derivados de catecolamina y prodrogas de los mismos | |
| AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
| AR056762A1 (es) | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos | |
| AR032361A1 (es) | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
| AR038404A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye | |
| AR041297A1 (es) | Derivados de 4-pirrolidino- fenil- bencil eter | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR065297A1 (es) | Formulaciones biodisponibles de compuestos heterociclicos | |
| AR040489A1 (es) | Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen | |
| AR043959A1 (es) | Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos | |
| AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR050698A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto | |
| AR040133A1 (es) | Derivados de n-acilamino bencil eter | |
| AR043055A1 (es) | Derivados de 1-(4-benzil-piperazin-1-il)-3- fenil-propenona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |